This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fazekas, F. Articles by Mamoli, B. Search for Related Content PubMed PubMed Citation Articles by Fazekas, F. Articles by Mamoli, B., for the Au Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

Department of Neurology, Karl-Franzens University, Graz

Florian Deisenhammer

Department of Neurology, Leopold- Franzens University, Innsbruck

Siegrid Strasser-Fuchs

Department of Neurology, Karl-Franzens University, Graz

Gerhard Nahler

CIS Clinical Investigation Support GmbH & Co KG, Vienna

Bruno Mamoli, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group

Department of Neurology , Hospital Rosenhügel, Vienna, Austria

Recently, the Austrian Immunoglobulin in Multiple Sclerosis (AIMS) study showed patients with relapsing - remitting multiple sclerosis to benefit from repeated administration of intravenous immunoglobulin (IVIg). To provide a more detailed understanding of IV/g's action we performed further analyses on the time course of treatment effects and in regard to the impact of clinical disability at study entry on patients' response to medication. The AIMS trial was a randomized, placebo-controlled, double blind, multicenter trial. It included 148 patients (IVIg : 75; placebo 73) who suffered from relapsing-remitting MS, were 15-65 years old and scored from I -6 on the Expanded Disability Status Score (EDSS). IVIg was given over 2 years in a monthly dosage of 0.15 - 0.2 g/kg body weight. Within the first 6 months of the trial clinical disability of IVIg treated patients improved significantly from a baseline EDSS of 3.33 ± 1.38 to a score of 3.05 ± 1.73 (P=0.002). This improvement was retained over the subsequent 18 months of the trial (final EDSS: 3.09 ± 1.62). In contrast, placebo-treated patients showed a slight trend for deterioration over the study period (baseline EDSS: 3.37± 1.67; final EDSS: 3.49± 1.83). IVIg treatment was associated with a significant reduction of relapses throughout the study which was independent of the patients' disability at baseline. The observation of clinical improvement in the early phase of IVIg medication may suggest the activation of repair mechanisms such as the promotion of remyelination while immunoregulatory effects would be expected as the cause of fewer exacerbations throughout the AIMS study. These hypotheses need to be tested in future trials.

Key Words: baseline disability • intravenous immunoglobulin • relapsing-remitting MS • remyelination • time course of treatment effects

Multiple Sclerosis, Vol. 3, No. 2, 137-141 (1997)
DOI: 10.1177/135245859700300214


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H F Petereit, D Reske, R Pukrop, M Maas-Enriquez, G Japp, P J. Jongen, H W Kolmel, S Merkelbach, H P Hartung, W D Heiss, et al. No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 66 - 71. [Abstract] [PDF]

				J Haas, M Maas-Enriquez, and H P Hartung Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years Multiple Sclerosis, October 1, 2005; 11(5): 562 - 567. [Abstract] [PDF]

				M. Filippi, M. A. Rocca, E. Pagani, G. Iannucci, M. P. Sormani, F. Fazekas, S. Ropele, O. R. Hommes, and G. Comi European Study on Intravenous Immunoglobulin in Multiple Sclerosis: Results of Magnetization Transfer Magnetic Resonance Imaging Analysis Arch Neurol, September 1, 2004; 61(9): 1409 - 1412. [Abstract] [Full Text] [PDF]

				A. Spalice, E. Properzi, V. Lo Faro, B. Acampora, and P. Iannetti Intravenous Immunoglobulin and Interferon: Successful Treatment of Optic Neuritis in Pediatric Multiple Sclerosis J Child Neurol, August 1, 2004; 19(8): 623 - 626. [Abstract] [PDF]

				C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]

				J. H. Noseworthy, P. C. O'Brien, B. G. Weinshenker, J. A. Weis, T. M. Petterson, B. J. Erickson, A. J. Windebank, J. P. Whisnant, K. A. Stolp-Smith, C. M. Harper Jr., et al. IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial Neurology, October 24, 2000; 55(8): 1135 - 1143. [Abstract] [Full Text] [PDF]

				D. Karussis and O. Abramsky Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No Arch Neurol, August 1, 1999; 56(8): 1028 - 1032. [Full Text] [PDF]

				P. F Smith and C. L Darlington Recent developments in drug therapy for multiple sclerosis Multiple Sclerosis, April 1, 1999; 5(2): 110 - 120. [Abstract] [PDF]